Thus, BIX or Jumonji histone demethylase-mediated regulation of BCAA metabolism may provide effective future strategies for EGFR-mutant NSCLC therapy and for overcoming EGFR-TKI resistance in NSCLC patients (Fig. 6f). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.